Walvax BioTech
Walvax Biotechnology Co., Ltd., engages in the research and development, manufacture, and distribution of vaccines in China. Its vaccine portfolio includes recombinant human papillomavirus bivalent, 13-valent pneumococcal polysaccharide conjugate, 23-valent pneumococcal polysaccharide, group ACYW135 meningococcal polysaccharide, group A and C meningococcal polysaccharide, group A and group C meni… Read more
Walvax BioTech (300142) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.003x
Based on the latest financial reports, Walvax BioTech (300142) has a cash flow conversion efficiency ratio of -0.003x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥-33.52 Million) by net assets (CN¥10.94 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Walvax BioTech - Cash Flow Conversion Efficiency Trend (2007–2024)
This chart illustrates how Walvax BioTech's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Walvax BioTech Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Walvax BioTech ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
SBI Cards and Payment Services Limited
NSE:SBICARD
|
0.007x |
|
Vishal Mega Mart Ord Shs
NSE:VMM
|
0.024x |
|
LG Display
KO:034220
|
0.078x |
|
Inventrust Properties Corp
NYSE:IVT
|
0.024x |
|
China State Construction International Holdings Limited
PINK:CCOHF
|
0.026x |
|
USA Rare Earth, Inc.
NASDAQ:USAR
|
0.057x |
|
SEACOAST BKG FLA DL-10
F:SBG1
|
N/A |
|
Allreal
PINK:ALRHF
|
N/A |
Annual Cash Flow Conversion Efficiency for Walvax BioTech (2007–2024)
The table below shows the annual cash flow conversion efficiency of Walvax BioTech from 2007 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥11.51 Billion | CN¥1.04 Billion | 0.090x | -9.47% |
| 2023-12-31 | CN¥11.40 Billion | CN¥1.13 Billion | 0.099x | -9.00% |
| 2022-12-31 | CN¥10.99 Billion | CN¥1.20 Billion | 0.109x | +55.00% |
| 2021-12-31 | CN¥10.00 Billion | CN¥705.28 Million | 0.071x | +384.76% |
| 2020-12-31 | CN¥7.85 Billion | CN¥114.19 Million | 0.015x | +32.94% |
| 2019-12-31 | CN¥5.67 Billion | CN¥62.02 Million | 0.011x | +188.19% |
| 2018-12-31 | CN¥5.26 Billion | CN¥-65.23 Million | -0.012x | +22.60% |
| 2017-12-31 | CN¥3.56 Billion | CN¥-57.04 Million | -0.016x | +37.18% |
| 2016-12-31 | CN¥3.52 Billion | CN¥-89.94 Million | -0.026x | -11.19% |
| 2015-12-31 | CN¥3.02 Billion | CN¥-69.41 Million | -0.023x | -11.83% |
| 2014-12-31 | CN¥3.21 Billion | CN¥-65.93 Million | -0.021x | +50.45% |
| 2013-12-31 | CN¥2.94 Billion | CN¥-121.73 Million | -0.041x | -267.52% |
| 2012-12-31 | CN¥3.17 Billion | CN¥78.38 Million | 0.025x | -27.05% |
| 2011-12-31 | CN¥2.71 Billion | CN¥91.98 Million | 0.034x | -0.28% |
| 2010-12-31 | CN¥2.55 Billion | CN¥86.71 Million | 0.034x | -92.77% |
| 2009-12-31 | CN¥174.69 Million | CN¥82.18 Million | 0.470x | +912.58% |
| 2008-12-31 | CN¥98.36 Million | CN¥-5.69 Million | -0.058x | -103.21% |
| 2007-12-31 | CN¥17.66 Million | CN¥31.85 Million | 1.804x | -- |